Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Author index

Page Path
HOME > Browse articles > Author index
Search
Kyu Il Ahn 1 Article
Efficacy of Combined Gemcitabine/Cisplatin Chemotherapy for Locally Advanced or Metastatic Urothelial Cancer
Kwan-Sik Bae, Kyu Il Ahn, Seung Hyun Jeon, Jung-Sik Huh, Sung-Goo Chang
Cancer Res Treat. 2006;38(2):78-83.   Published online April 30, 2006
DOI: https://doi.org/10.4143/crt.2006.38.2.78
AbstractAbstract PDFPubReaderePub
Purpose

We wanted to determine and report on the outcome of combined gemcitabine/cisplatin chemotherapy for patients suffering with locally advanced or metastatic urothelial cancer.

Materials and Methods

Between July 1999 and December 2004, 43 selected patients were enrolled in this study. Group 1 (the adjuvant chemotherapy group) had undergone radical surgery with removal of evident tumor from the following primary sites: bladder (n=8), renal pelvis (n=7) and ureter (n=3). Group 2 (the salvage chemotherapy group) had undergone palliative surgery with a remnant tumor at the following primary sites; bladder (n=23) and renal pelvis (n=2). All the patients were given gemcitabine/ciplatin and they evaluated for the therapeutic effect and toxicity. The patients were initially treated with gemcitabine 1000 mg/m2 intravenously for 30 minutes on days 1, 8 and 15 of a 28-day cycle, and cisplatin 70 mg/m2 was administered intravenously on day 1 using prehydration measures.

Results

Group 1: The median follow-up period was 16.5 months. The mean age was 63 years (males: 15 cases, females: 3 cases), and eleven patients (61%) remained alive. The estimated median relapse-free survival period and 2-year survival rate were 24 months and 63%, respectively. Group 2: the median follow-up period was 20 months, the mean patient age was 63.8 years (males: 22 cases, females: 3 cases), and nine patients (36%) remained alive. The overall response and 2-year survival rates were 36% and 43%, respectively. Toxicities: Grade 3 toxicities developed in 14 cycles during the total 232 cycles. Grade 4 toxicity did not occur.

Conclusions

The results of this study confirm that adjuvant and salvage chemotherapy with using gemcitabine and cisplatin is tolerable and safe.

Citations

Citations to this article as recorded by  
  • Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)
    Ioannis Boukovinas, Nikolaos Androulakis, Nikolaos Kentepozidis, Aris Polyzos, Pavlos Papakotoulas, Nikolaos Ziras, Athanasios Kotsakis, Nikolaos Vardakis, Athanasios Karampeazis, Vassilis Markos, Athanasios Kostakopoulos, Constantine A. Constantinides, G
    Cancer Chemotherapy and Pharmacology.2012; 69(2): 351.     CrossRef
  • 8,935 View
  • 41 Download
  • 1 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP